Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083408 · ClinicalTrials.gov registry record · Phase 2
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
A Phase 2 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00083408 is a Phase 2 study that has completed, run by University of Arkansas. The registered enrollment target is 20 participants.
The verdict
NCT00083408, a Phase 2 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this research is to study how helpful the combination of thalidomide and Pamidronate is in controlling multiple myeloma and to study any side effects that may be experienced.
Interventions
- DRUG Thalidomide
- DRUG Pamidronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 1998-03 |
| Est. Completion | 2005-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00083408
The ClinicalTrials.gov registry entry for NCT00083408 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Thalidomide is the first listed.
NCT00083408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00083408 about?
NCT00083408 is a clinical study titled "Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide". The purpose of this research is to study how helpful the combination of thalidomide and Pamidronate is in controlling multiple myeloma and to study any side effects that may be experienced.
What is the current status of trial NCT00083408?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 1998-03. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00083408?
The interventions under investigation include: Thalidomide (DRUG), Pamidronate (DRUG).
Who is sponsoring clinical trial NCT00083408?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.